Equities

QLI

KYG7307E1070

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
0.6901 ^USD	-3.75%		+6.17%	-10.54%

02-15	Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2023	CI
01-12	Qilian International Gets Nasdaq Extension to Meet Minimum Bid Price Rule; Shares Rise	MT

Qilian International Holding Group Limited Reports Earnings Results for the Half Year Ended March 31, 2023

August 04, 2023 at 04:15 pm

Qilian International Holding Group Limited reported earnings results for the half year ended March 31, 2023. For the half year, the company reported sales was USD 29.16 million compared to USD 32.09 million a year ago. Net income was USD 0.495521 million compared to USD 0.087862 million a year ago.

Basic earnings per share from continuing operations was USD 0.01.

Latest news about QILN HLDG

Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2023	02-15	CI
Qilian International Gets Nasdaq Extension to Meet Minimum Bid Price Rule; Shares Rise	01-12	MT
Qilian International Holding Group Limited Reports Earnings Results for the Half Year Ended March 31, 2023	23-08-04	CI
Qilian International Holding Group Limited Announces Board Changes	23-07-25	CI
Qilian International Gets Noncompliance Notice From Nasdaq	23-07-17	MT
Qilian International Holding Group Limited Announces Board Changes	23-06-14	CI
Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2022	23-04-19	CI
Qilian International Holding Group Ltd Declares Special Cash Dividend, Payable on or About March 6, 2023	23-02-16	CI
Qilian International Holding Group Limited Reports Earnings Results for the Half Year Ended March 31, 2022	22-09-30	CI
Qilian International Earnings Drop to Breakeven in Latest Six-Month Reporting Period, Revenue Climbs 7%	22-09-30	MT
Qilian International Holding Group Limited Announces Board Changes	22-04-15	CI
Qilian International Holding Group Limited Intend in 2022 and Beyond to Complete the Construction of a Pig By-Product Processing Facility	22-02-11	CI
Qilian International Holding Group Limited Reports Earnings Results for the Full Year Ended September 30, 2021	22-02-11	CI
Qilian International Obtains Approval to Sell Nitrofurantoin Enteric-coated Tablets	22-01-19	MT
Qilian International Holding Group Limited Receives Approval for the Sale of Its Newly Developed Nitrofurantoin Enteric-Coated Tablets	22-01-19	CI
Qilian Subsidiary Developing Vitacoenzyme to Prevent Gastric Cancer	21-11-15	MT
Qilian International Holding Group Limited Announces Initiation of Development of New Drug for Gastric Cancer Prevention	21-11-15	CI
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts it into Production	21-10-26	CI
Qilian International : Unit Wins Gansu Province OK to Export Oxytetracycline API to Egypt	21-10-13	MT
Qilian International Holding Group Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended March 31, 2021	21-09-16	CI
Certain Ordinary Shares of Qilian International Holding Group Limited are subject to a Lock-Up Agreement Ending on 12-JUL-2021.	21-07-11	CI
Qilian International : to Invest $84 Million Pig By-product Processing Project	21-07-09	MT
Qilian International : Enters Exclusive Agency Agreement With Henan Kangzhiyuan Pharmaceutical	21-05-05	MT
Qilian International : Edging Higher in Late Trade After FY20 EPS Slips to $0.17; Revenue Increases 9% Over Year-Ago Levels	21-02-11	MT
Qilian International Holding Group Limited Announces Consolidated Earnings Results for the Year Ended September 30, 2020	21-02-11	CI

Chart QILN HLDG

Duration

Period

More charts

Company Profile

Qilian International Holding Group Ltd is a China-based company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The Company operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. Its main brand is Qilian Shan. The Company principally operates its businesses within the domestic market.

Sector

More about the company

Income Statement Evolution

More financial data